Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company
Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
First Person Treated in Germany; Reimbursement Discussions on Track in France and Italy
In the U.S., ROCTAVIAN Now Commercially Available and Hemophilia Treatment Centers Have Begun Screening